Melphalan/Total Body Irradiation–Conditioned Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Primary Plasma Cell Leukemia

Landsburg, Daniel J.; Vogl, Dan T.; Plastaras, John P.; Stadtmauer, Edward A.

doi:10.1016/j.clml.2014.07.012

Cited by 8 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this intensive approach consistently was found to be associated with high rates of treatment‐related mortality (35%‐55%), which abrogated any benefits derived from improved disease control. Several recent small studies have evaluated less intensive, but still myeloablative, regimens and have demonstrated 3‐year OS rates of approximately 30% and 1‐year treatment‐related mortality rates of 19% to 37% . To the best of our knowledge, no contemporary systematic studies have evaluated more recent approaches to myeloablative conditioning.…”

Section: Introductionmentioning

confidence: 99%

Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy

Bair

Brandstadter

Ayers

et al. 2020

Cancer

Self Cite

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HCT) has been an integral component in the treatment of many hematologic malignancies. Since the development of HCT nearly 50 years ago, the role of this modality has evolved as newer treatment approaches have been developed and integrated into the standard of care. In the last decade, novel and highly active targeted therapies and immunotherapies have been approved for many hematologic malignancies, raising the question of whether HCT continues to retain its prominent role in the treatment paradigms of various hematologic malignancies. In this review, the authors have described the current role of autologous and allogeneic HCT in the treatment of patients with acute leukemias, aggressive B-cell lymphomas, and multiple myeloma and discussed how novel targeted therapies and immunotherapies have changed the potential need, timing, and goal of HCT in patients with these diseases.

show abstract

Section: Introductionmentioning

confidence: 99%